Your browser doesn't support javascript.
loading
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Jeay, Sébastien; Gaulis, Swann; Ferretti, Stéphane; Bitter, Hans; Ito, Moriko; Valat, Thérèse; Murakami, Masato; Ruetz, Stephan; Guthy, Daniel A; Rynn, Caroline; Jensen, Michael R; Wiesmann, Marion; Kallen, Joerg; Furet, Pascal; Gessier, François; Holzer, Philipp; Masuya, Keiichi; Würthner, Jens; Halilovic, Ensar; Hofmann, Francesco; Sellers, William R; Graus Porta, Diana.
Afiliação
  • Jeay S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Gaulis S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Ferretti S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Bitter H; Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Ito M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Valat T; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Murakami M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Ruetz S; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Guthy DA; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Rynn C; Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Jensen MR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Wiesmann M; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Kallen J; Center of Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Furet P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Gessier F; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Holzer P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Masuya K; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Würthner J; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Halilovic E; Translational Clinical Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Hofmann F; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Sellers WR; Disease Area Oncology, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Graus Porta D; Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Elife ; 42015 May 12.
Article em En | MEDLINE | ID: mdl-25965177
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Biomarcadores / Regulação Neoplásica da Expressão Gênica / Proteína Supressora de Tumor p53 / Seleção de Pacientes / Proteínas Proto-Oncogênicas c-mdm2 / Isoquinolinas / Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Biomarcadores / Regulação Neoplásica da Expressão Gênica / Proteína Supressora de Tumor p53 / Seleção de Pacientes / Proteínas Proto-Oncogênicas c-mdm2 / Isoquinolinas / Neoplasias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2015 Tipo de documento: Article